Compare McKesson Corporation (MCK) vs YieldMax Magnificent 7 Fund of Option Income ETFs (YMAG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
McKesson Corporation vs YieldMax Magnificent 7 Fund of Option Income ETFs — how do they compare? McKesson Corporation trades at $938.84 (market cap $108.46B), while YieldMax Magnificent 7 Fund of Option Income ETFs trades at $11.44 (market cap $296.92M). The key difference: McKesson Corporation is far larger — about 365.3× YieldMax Magnificent 7 Fund of Option Income ETFs's market cap, and McKesson Corporation pays a 0.4% dividend while YieldMax Magnificent 7 Fund of Option Income ETFs pays none. Which is the better fit depends on your goals — on Pluang, investors hold McKesson Corporation for 74 Days and YieldMax Magnificent 7 Fund of Option Income ETFs for 62 Days on average.
| MCK | YMAG | |
|---|---|---|
Market Cap | $108.46B | $296.92M |
Volume | 712,607 | 1,023,545 |
Sector | Health | Income / Options Overlay |
52-Week High | $995.69 | $15.68 |
52-Week Low | $725.17 | $10.76 |
Typical Hold Time | 74 Days | 62 Days |
Enterprise Value | $115.00B | — |
Dividend Yield | 0.4% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
McKesson Corporation (MCK) trades at $930.25, up 2.19% with strong technical momentum and bullish analyst sentiment. The stock shows consistent earnings beats with Q2 2026 EPS of $9.93 exceeding expectations of $9.56. Recent news highlights the extension of McKesson's pharmaceutical distribution agreement with CVS Health through 2032, reinforcing long-term revenue visibility. Revenue growth remains robust, climbing from $264.0B in 2022 to $359.1B in 2025, though net margins are thin at 1.12%.
McKesson presents a favorable risk-reward profile with 81% analyst buy ratings and a $956.43 consensus price target offering 2.8% upside. Key risks include margin pressure from drug pricing dynamics and policy uncertainty. The company's strong cash flow generation ($6.1B operating cash flow in 2025) and strategic focus on oncology and specialty distribution support continued growth, though investors should monitor debt levels and competitive pressures in healthcare distribution.
YMAG trades at $11.44, down 0.44% on the day, with a bearish technical signal driven by moving averages. The ETF maintains a consistent weekly dividend distribution schedule, with recent payouts ranging from $0.07 to $0.11 per share. Technical indicators show neutral oscillators but bearish momentum signals, with all support and resistance levels clustered around $11.
The outlook remains cautious due to the bearish technical setup and potential NAV volatility from underlying option strategies. Income-focused investors may find the distribution yield attractive, but price stability concerns persist given the concentrated support level and negative momentum indicators.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About McKesson Corporation
McKesson is a leading wholesaler of branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospitals networks, and healthcare providers. Along with AmerisourceBergen and Cardinal Health, the three account for well over 90% of the U.S. pharmaceutical wholesale industry. McKesson is currently divesting from its pharmaceutical wholesale and distribution in Europe and Canada in order to redeploy capital to strategic growth areas in the U.S. (oncology network and ecosystem, and biopharma services). Additionally, the company supplies medical-surgical products and equipment to healthcare facilities and provides a variety of technology solutions for pharmacies.
Read more on MCK →About YieldMax Magnificent 7 Fund of Option Income ETFs
YMAG is an actively managed 'fund of funds' that provides equal-weighted exposure to the seven YieldMax ETFs tracking the 'Magnificent 7' tech giants (Apple, Microsoft, Alphabet, Amazon, Nvidia, Meta, and Tesla). It seeks to generate high current income by harvesting option premiums across these leaders, offering a streamlined way to access concentrated tech volatility in an income-producing format.
Read more on YMAG →
